Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

This study has been withdrawn prior to enrollment.
(Amendment to study compound development programme)
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01194193
First received: August 18, 2010
Last updated: May 13, 2011
Last verified: May 2011
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given